Clinical trial NCT00039195 (phase 2, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine sulfate
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed aggressive diffuse large B-cell lymphoma

          -  CD20-positive disease

          -  Age-adjusted International Prognostic Index II or III defined by the presence of at
             least 1 of the following:

               -  Karnofsky performance status 10-70%

               -  Lactate dehydrogenase greater than 200 U/L

               -  Stage III or IV disease

          -  Positron emission tomography avid measurable disease

          -  No CNS involvement

        PATIENT CHARACTERISTICS:

        Age:

          -  18 to 64

        Performance status:

          -  See Disease Characteristics

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count greater than 1,000/mm^3

          -  Platelet count greater than 50,000/mm^3

        Hepatic:

          -  Bilirubin less than 2.0 mg/dL unless history of Gilbert's disease or pattern
             consistent with Gilbert's disease

          -  Hepatitis B surface antigen and hepatitis C antibody negative

          -  No chronic, active, or persistent hepatitis

        Renal:

          -  Creatinine no greater than 1.5 mg/dL OR

          -  Creatinine clearance greater than 60 mL/min

          -  No chronic renal insufficiency

        Cardiovascular:

          -  Ejection fraction at least 50% by echocardiogram or MUGA scan

          -  No myocardial infarction within the past 6 months

          -  No unstable angina

          -  No cardiac arrhythmias except chronic atrial fibrillation

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception

          -  HIV negative

          -  No other medical illness that would preclude study

          -  No uncontrolled infection

          -  No other malignancy within the past 5 years except curatively treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior biologic therapy for malignancy

        Chemotherapy:

          -  No prior chemotherapy for malignancy

        Endocrine therapy:

          -  Prior steroids allowed if received no more than 1 week of therapy

        Radiotherapy:

          -  No prior radiotherapy for malignancy

        Surgery:

          -  No prior surgery for malignancy

        Other:

          -  No other prior therapy for malignancy